8.13

0.68% 0.055

After Hours: 8.13

Atara Biotherapeutics Inc (ATRA)

Overview News Price History Option Chain Financials Why ATRA Down? Discussions Forecast

Atara Biotherapeutics Inc stock is traded at $8.13, with a volume of 64,536. It is up +0.68% in the last 24 hours and up +6.97% over the past month. Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Previous Close:

$8.075

Open:

$8.01

24h Volume:

64,536

Relative Volume:

0.52

Market Cap:

$46.21M

Revenue:

$8.57M

Net Income/Loss:

$-276.13M

P/E Ratio:

-2.7653

EPS:

-2.94

Net Cash Flow:

$-194.20M

1W Performance:

+10.46%

1M Performance:

+6.97%

6M Performance:

-53.14%

1Y Performance:

-78.03%

1-Day Range:

$8.01

$8.66

1-Week Range:

$7.10

$8.66

52-Week Range:

$4.965

$45.75

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Name

Atara Biotherapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

805-623-4244

Address

2380 CONEJO SPECTRUM ST, THOUSAND OAKS, CA

Employee

165

Twitter

@Atarabio

Next Earnings Date

2024-10-30

Latest SEC Filings

ATRA's Discussions on Twitter

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-20-22	Downgrade	Citigroup	Neutral → Sell
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-13-22	Downgrade	Stifel	Buy → Hold
May-10-22	Downgrade	Citigroup	Buy → Neutral
May-13-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-09-20	Downgrade	Citigroup	Buy → Neutral
Dec-08-20	Reiterated	H.C. Wainwright	Buy
Nov-10-20	Reiterated	H.C. Wainwright	Buy
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy
Apr-23-20	Upgrade	Citigroup	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral
Sep-27-19	Downgrade	Goldman	Neutral → Sell
Sep-16-19	Downgrade	Jefferies	Buy → Hold
Jun-04-19	Upgrade	Citigroup	Sell → Neutral
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy
Jan-23-19	Initiated	Mizuho	Buy
Apr-10-18	Initiated	JP Morgan	Overweight
Mar-16-18	Initiated	Guggenheim	Neutral
Mar-05-18	Reiterated	Jefferies	Buy
Feb-28-18	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-15-18	Downgrade	Citigroup	Neutral → Sell
Jan-03-18	Upgrade	Citigroup	Sell → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Atara Biotherapeutics Inc Stock (ATRA) Latest News

Sep 27, 2024

Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart

Sep 27, 2024

Sep 24, 2024

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 06, 2024

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St

Sep 06, 2024

Sep 05, 2024